Cargando…
Access to Cancer Drugs in Canada
Autor principal: | Wheatley-Price, Paul |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9600617/ https://www.ncbi.nlm.nih.gov/pubmed/36290875 http://dx.doi.org/10.3390/curroncol29100598 |
Ejemplares similares
-
The Pathway for New Cancer Drug Access in Canada
por: Gotfrit, Joanna, et al.
Publicado: (2022) -
Determinants of the Cancer Drug Funding Process in Canada
por: Gotfrit, Joanna, et al.
Publicado: (2022) -
A focus on access to health care in Canada
por: Patrick, Kirsten, et al.
Publicado: (2023) -
Drug Delivery Technology Development in Canada
por: Wasan, Kishor M., et al.
Publicado: (2019) -
Should Canada adopt managed access agreements in Canada for expensive drugs?
por: McPhail, Melanie, et al.
Publicado: (2023)